Verisk Maplecroft Named Best Specialist ESG Ratings Provider by ESG Investing
LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Verisk’s global risk analytics business, Verisk Maplecroft, was named Best Specialist ESG Ratings Provider at the ESG Investing Awards.
The award recognises Verisk Maplecroft’s Sovereign ESG Ratings, which provide investors with the most comprehensive picture available of ESG risks and opportunities across the entire current and potential sovereign issuer universe. Verisk is a global data analytics and technology provider for the global insurance industry. The company is committed to working with clients to build global resilience for individuals, communities and businesses.
The Ratings are part of Verisk’s growing suite of sustainability and resilience exposure analytics, which include extreme event models and global geospatial datasets covering the full spectrum of ESG, political and climate risks.
“This award is testament to our team’s dedication to helping sovereign ESG investors use geospatial data to develop a deep-set understanding of critical ESG issues that result in tangible and sustainable outcomes in government bond markets,” said Verisk Maplecroft President Matt Moshiri. “We will continue to refine, innovate and release data solutions to ESG investors across sovereign debt and other asset classes, including equities, real estate and commodities.”
The ESG Investing Awards 2023 are the only awards devoted to assessing and evaluating the best companies involved in all areas of ESG investing across the globe. Submissions were assessed by a panel of independent judges including financial market professionals, academics and independent experts. ESG Investing is a division of Global Markets Media.
Verisk Maplecroft was also nominated as a finalist in the Best Specialist ESG Research category for its analysis of the sovereign ESG landscape that showcased research findings from its Sovereign ESG Ratings. This included demonstrating that ESG issues, including human rights, are highly material for sovereign debt on multiple levels.
Verisk sets a new global standard for sovereign ESG analysis
Verisk Maplecroft’s award-winning Sovereign ESG Ratings, which feature six years of quarterly historical data, draw on approximately 350 of 1200+ indicators across 37 separate issues and nine ESG dimensions. Their novel methodology, based on cluster analysis, captures the non-linear complexity of the sovereign ESG world more effectively than traditional weighted averages.
The data within the Ratings draw exclusively from Verisk Maplecroft’s vast array of unstructured, geospatial, expert-derived and structured sources that go far beyond the lagging datasets that have historically been used to track sovereign ESG issues. Both the underlying data and the Ratings themselves are current, dynamic and fully independent of government influence.
Verisk was also recently recognised for its commitment to ESG and business performance, ranking third on Investor’s Business Daily’s 100 Best ESG Company List. Learn more about Verisk’s ESG efforts.
About Verisk Maplecroft
Verisk Maplecroft, a Verisk business (Nasdaq: VRSK), is a leading geospatial risk analytics company specialising in global ESG and political risk intelligence for institutional investors and multinational corporations. The company combines the world’s most comprehensive portfolio of global risk data with expert analysis to deliver an integrated approach to risk, which enables clients to enhance the sustainability and resilience of their investments and operations. Among investment fund managers and asset owners, the company is a trusted, independent source of data, intelligence and advice for incorporating ESG, climate change, natural capital, human rights and political risk factors across multiple asset classes, notably sovereign debt. For more information visit: www.maplecroft.com
Verisk (Nasdaq: VRSK) provides data-driven analytic insights and solutions for the insurance industry. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk empowers customers to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global issues, including climate change and extreme events as well as political and ESG topics. With offices in more than 15 countries, Verisk consistently earns certification by Great Place to Work and fosters an inclusive culture where all team members feel they belong. For more, visit Verisk.com and the Verisk Newsroom.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Aduro Clean Technologies Increases Size of Private Placement to $4 Million29.3.2023 02:12:40 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SARNIA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into feedstocks and higher-value fuels, is pleased to announce that, further to its news release dated March 8, 2023, it has increased the size of its non-brokered private placement of units (the “Units”) at $0.93 per Unit for gross proceeds of a minimum of $1,999,965 and up to a maximum of $4,000,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”) at a price o
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform28.3.2023 22:05:00 CEST | Press release
SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. “This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disor
Development of the Annual General Meeting of the BANK of Greenland28.3.2023 22:03:19 CEST | Press release
Minutes of General Meeting To Nasdaq OMX Copenhagen 28 March 2022 Company announcement no. 05/2023 Development of the Annual General Meeting of the BANK of Greenland Today, the BANK of Greenland held its Annual General Meeting in accordance with the Articles of Association and the previously published notice convening the meeting. The Annual General Meeting was attended by shareholders representing 1,049,468 votes, of which 612,498 votes were given by proxy to the Board of Directors, 62,821 votes were covered by instructions to holders of power of attorney and 115,455 votes of correspondance. The Board of Directors' Report on the Bank's activities during the past year The Chairman of the Board of Directors Gunnar í Liða presented the Board of Directors' report on the Bank's activities during the past year. The report of the Board of Directors was noted. The Chairman's report can be viewed on the Bank's website at www.banken.gl. The minutes of the Annual General Meeting will also be pub
Forløb af ordinær generalforsamling i GrønlandsBANKEN28.3.2023 22:03:19 CEST | pressemeddelelse
Referat af Generalforsamling Til Nasdaq OMX Copenhagen 28. marts 2023 Selskabsmeddelelse nr. 05/2023 Forløb af ordinær generalforsamling i GrønlandsBANKEN GrønlandsBANKEN har i dag afholdt ordinær generalforsamling i henhold til vedtægterne og tidligere offentliggjort indkaldelse. Generalforsamlingen var repræsenteret med 1.049.468 stemmer, heraf var 612.498 stemmer givet som fuldmagt til bestyrelsen, 62.821 stemmer var givet som instruktionsfuldmagt, mens 115.455 var afgivet som brevstemme. Bestyrelsens beretning om bankens virksomhed i det forløbne år Bestyrelsesformand Gunnar í Liða aflagde bestyrelsens beretning om bankens virksomhed i det forløbne år. Bestyrelsens beretning blev taget til efterretning. Formandens beretning kan ses på bankens hjemmeside www.banken.gl Generalforsamlingens protokollat vil senest 14 dage efter generalforsamlingens afholdelse ligeledes blive lagt på bankens hjemmeside. Godkendelse af årsrapporten for 2022, meddelelse om decharge for bestyrelse og direk
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants28.3.2023 22:00:00 CEST | Press release
Company announcement – No. 8 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 34,594 divided into 34,594 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which ar